Delaware Valley Node of the Clinical Trials Network

特拉华州山谷节点（DVN）的PI、Co-PI、关键人员和其他工作人员具有相当的广度， 在治疗物质使用障碍患者和开展临床试验方面的丰富经验， 药理学、行为学和卫生服务研究，以及侧重于艾滋病毒、遗传学和 神经成像此应用程序通过在以下文件中提供DVN功能来响应RFA的特定要求： 三个部分：A部分是对DVN的描述，包括它如何对CTN的总体目标做出贡献; 有关教师，工作人员和社区治疗提供者（CTPs）的信息;说明其组织结构图 管理结构;以及描述我们的组织组件如何工作以实现多站点的叙述 试验和传播循证实践。该DVN借鉴了大学的相当大的优势， 宾夕法尼亚州，治疗研究所，以及来自宾夕法尼亚州，新泽西和特拉华州的领先CTP。 重要的是，所有DV Node CTP都有作为实践/研究合作伙伴的经验和热情。加强我们 有能力实施与艾滋病毒和其他传染病有关的研究，两个传染病诊所（IDC） 已添加到DVN。B部分是一份进度报告，总结了过去五年的成就 包括：DVN参与的所有CTN方案、辅助研究和平台研究的入组数据。 首先介绍了DV Node提出的10个研究概念，然后对DVN两个协议进行了总结 被批准领导。这些议定书中采用的程序、吸取的具体经验教训以及 结果进行了简要描述。我们对CTN基础设施及其持续管理的贡献如下： 总结，沿着对国防部虚拟网络的培训、教育、传播和技术转让的描述 活动C部分是题为“将药物滥用治疗纳入传染病”的研究概念 诊所。“它建议测试两种模型来治疗患有HIV或HepC并接受抗病毒治疗的个体 在传染病诊所（IDC）：综合药物滥用治疗在IDC现场;或转介到附近！ 药物滥用项目，也就是常规治疗。主要成果是减少物质使用，减少 HIV危险行为和抗病毒治疗依从性。如果CTN接受了阳性结果， 可以减少物质使用并改善患有物质使用障碍的人的治疗结果， HIV和HepC，并减少传播HIV和其他传染病的行为。

The PI, Co-Pi, Key Personnel and other staff of the Delaware Valley Node (DVN) have substantial breadth and depth of experience in treating persons with substance use disorders and carrying out clinical trials involving pharmacologic, behavioral, and health services research, as well as studies focusing on HIV, genetics, and neuroimaging. This application responds to the specific requirements of the RFA by presenting the DVN capabilities in three parts: Part A is a Description of the DVN including how it contributes to the overall goals of the CTN; information about faculty, staff, and community treatment providers (CTPs); an organizational chart illustrating its management structure; and a narrative describing how our organizational components work to implement multi-site trials and disseminate evidence-based practices. The DVN draws upon the considerable strengths of the University of Pennsylvania, the Treatment Research Institute, and leading CTPs from Pennsylvania, New Jersey and Delaware. Importantly, all DV Node CTPs have experience and enthusiasm as practice/research partners. To strengthen our ability to implement studies related to HIV and other infectious diseases, two infectious disease clinics (IDCs) have been added to the DVN. Part B is a Progress Report with a summary of accomplishments over the past five years including: enrollment data for all CTN protocols, ancillary studies, and platform studies in which the DVN participated. The ten research concepts proposed by the DV Node are presented, followed by a summary of two protocols the DVN was approved to lead. The procedures employed in these protocols, specific lessons learned, and contributions that resulted are briefly described. Our contributions to the CTN infrastructure and its ongoing management are summarized, along with a description of the DVN's training, education, dissemination, and technology transfer activities. Part C is a Research Concept entitled "Integrating Substance Abuse Treatment into Infectious Disease Clinics." It proposes to test two models for treating individualswho have HIV or HepC and receive antiviral treatment in Infectious Disease Clinics (IDCs): integrated substance abuse treatment onsite at the IDC; or referral to a nearby! substance abuse program, which is treatment as usual. Primary outcomes are reduction in substance use, reduction in HIV risk behavior, and compliance with antiviral treatment. If accepted by the CTN with positive results, the findings could reduce substance use and improve the outcome of treatment for persons with substance use disorders who have HIV and HepC, and reduce behaviors that spread HIV and other infectious diseases.